patients appear to have a deficiency of the platelet ADP receptor coupled to inhibition of adenylyl cyclase; the P2Y 1 receptor has been shown to be normal in one of the patients (21) . This still-unidentified P2 receptor is thought to be coupled to a G protein of α i2 subtype (22) and hence could belong to the P2Y metabotropic receptor family. A full aggregation response to ADP requires activation of both P2 receptors (10, 11, 23) , but it is not yet clear how synergy between these 2 receptors may occur. In addition, to date no molecular entity has been reported to have the properties of a P2 receptor negatively coupled to adenylyl cyclase. Thus, doubts still remain as to whether the P2Y 1 receptor may exist in different conformations, which could account for a differential coupling to the Gq or Gi alpha subunits of G proteins. Platelets also express the ionotropic P2X 1 receptor (24) (25) (26) (27) (28) . Its role in ADPinduced platelet aggregation is unknown and seems to be discrete, although this receptor is responsible for a unique fast calcium entry into platelets (24, 29) . The aims of the present study were (a) to define the role of the P2Y 1 receptor in hemostasis and thrombosis and (b) to determine whether or not the unidentified P2 receptor coupled to inhibition of adenylyl cyclase is distinct from the P2Y 1 receptor and independently expressed in platelets. We report that targeted disruption of the P2Y 1 receptor results in impaired platelet aggregation and inhibition of acute thrombosis induced by infusion of ADP or collagen and adrenaline. We also show that platelets from P2Y 1 -deficient mice are still responsive to ADP through the P2 receptor coupled to inhibition of adenylyl cyclase.
Methods
Materials. ADP was purchased from Roche Molecular Biochemicals (Meylan, France). U46619, thrombin, fura-2/acetoxymethyl ester (fura-2/AM), adrenaline, and type I bovine collagen (for aggregation studies) were from Sigma (Saint-Quentin Fallavier, France). Equine collagen (Kollagenreagent Horm), used in the thromboembolism experiments, was purchased from Hormon Chemie (München, Germany). Human fibrinogen was from Kabi (Stockholm, Sweden). AR-C69931MX was kindly provided by Astra Charnwood (Loughborough, United Kingdom), and clopidogrel was from Sanofi Recherche (Toulouse, France). The radioimmunoassay cAMP measurement kit was purchased from Amersham Pharmacia Biotech (Les Ulis, France).
Targeted inactivation of the P2Y 1 gene. A 0.57-kb cDNA probe corresponding to mouse P2Y 1 cDNA was prepared by PCR after reverse transcription of total RNA isolated from mouse hearts. The PCR primers were derived from the published sequence of mouse P2Y 1 cDNA (30) (sense primer: 5′-CCGGTTTCCAGTTCTAC-TACCTGCCG-3′; and antisense primer: 5′-CATAACAGC-CCAAGATCAGCACCAAAGG-3′). This probe was used to screen a 129/Sv genomic library (kind gift of P. Chambon, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Strasbourg, France). A 12.6-kb fragment was cloned and entirely sequenced in both directions (accession no. AJ245636). The mouse P2Y 1 gene contains 1 intron as compared with the mouse cDNA cloned previously (30) , located in the 3′ untranslated region at position 4228 to 6524. Six polyadenylation signals are present at base 4401, 4611, 9721, 10610, 10636, and 11842. The first 6 kb containing the entire coding sequence was subcloned into pBluescript-KS (Stratagene, La Jolla, California, USA), and the coding sequence was interrupted by insertion of a PGK-neopoly(A) cassette (gift of M. McBurney, University of Ottawa, Ottawa, Ontario, Canada) in position 3208 (Figure 1a) . The targeting vector was linearized and electroporated into the P1 embryonic stem (ES) cell line (129/Sv mouse strain; IGBMC, Strasbourg, France) and neomycin-resistant clones were isolated and screened by PCR for homologous recombination. Oligonucleotides used were: neomycin resistance gene 5′-ACTCTGGGGTTCGAAATGACCGACCAAGCG-3′ and 5′-GCCTTCTATCGCCTTCTTGACGAGTTCTTC-3′; P2Y 1 gene 5′-CTTCATGGACCTGAGTAATAAGACATTAGGC-3′ and 5′-AAATGGAAGCACTCCAAAAATCTCCCAGATC-3′. Southern blot analyses were performed to confirm the PCR results, using as a probe a fragment of the P2Y 1 gene from base 6847 to base 8179, outside the construction, which distinguishes between the wild-type allele (12 kb) and the recombinant allele (9.5 kb).
Generation of P2Y 1 -deficient mice. Targeted ES cells were introduced into C57BL/6 mouse blastocysts as described by Lufkin et al. (31) . Male chimeras were mated with C57BL/6 females and heterozygous offspring (50% 129/Sv and 50% C57BL/6 strain) were intercrossed to obtain animals homozygous for the null mutation (P2Y 1 -/-mice) and homozygous for the wild-type allele (P2Y 1 +/+ mice). Both control P2Y 1 +/+ and P2Y 1 -/-mice used in this study were at the F 3 generation, resulting from intercrossing between several homozygous F 2 littermates.
Bleeding time. Male and female mice (20-30 g ) were anesthetized by intraperitoneal injection of 150 µL of a mixture of 0.08% xylazine base (Rompun, Bayer, France) and 1.6% ketamine (Imalgen 1000; Mérial, Lyon, France). A cut was made longitudinally in the mouse tail using a Simplate device (Organon Teknika B.V., Boxtel, The Netherlands). The tail was immediately immersed in 0.9% isotonic saline at 37°C. The bleeding time was defined as the time required for arrest.
Platelet aggregation. Blood was drawn from the abdominal aorta into acid-citrate-dextrose solution (ACD) (1 vol ACD/6 vol blood) and pooled (10 mL). Washed platelet aggregation was measured turbidimetrically as described previously (11) . Final platelet suspension was adjusted to 2.10 5 platelets/µL and kept at 37°C. Fibrinogen (0.2 mg/mL) was added before stimulation by ADP.
Calcium measurements. Washed platelets were loaded with fura-2/AM, and intracellular calcium movements were measured in a spectrofluorometer PTI Deltascan (Photon Technology International Inc., South Brunswick, New Jersey, USA) using excitation wave-lengths of 340 and 380 nm and fluorescence emission detection at 510 nm, as described previously (11) .
Cyclic AMP measurements. Platelets (8.10 4 /µL) were stimulated at 30-second intervals with either vehicle (Tyrode's buffer without Ca 2+ or Mg 2+ ) (11), or various agonists, or antagonists, in a final volume of 250 µL. The reaction was stopped by addition of 50 µL of 6.6 M perchloric acid, and intracellular cAMP was determined by radioimmunoassay (11) .
Electron microscopy. Platelets were directly fixed in the aggregation cuvette with 2.5% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.2, containing 2% sucrose. Platelets were then processed as described previously (32) . Ultrathin sections were observed under a Philips CM120 Biotwin electron microscope (Philips Consumer Electronics B.V., Eindhoven, The Netherlands) at 120 kV.
ADP-induced thromboembolism. The jugular vein of anesthetized male mice was exposed surgically, and increasing doses of ADP were injected intravenously within 3 to 4 seconds. After 50 to 60 seconds, blood was collected by intracardiac puncture, recovered in EDTA (6 mM), and platelets were counted optically under a phase-contrast microscope.
Thromboembolism induced by collagen and epinephrine. A mixture of collagen (0.5 mg/kg) and epinephrine (60 µg/kg) was injected into the jugular vein of anesthetized male mice (33) . The incisions of surviving mice were stitched, and they were allowed to recover.
Results

Targeted disruption of the P2Y 1 receptor gene in ES cells by homologous recombination.
The coding region of the mouse P2Y 1 gene was interrupted by insertion of a neomycin resistance gene cassette (Figure 1a) , and homologous recombination events were screened. A targeting frequency of 4% was observed and 2 targeted ES clones were injected into blastocysts to generate chimeric mice. Mice homozygous for either the targeted allele or the wild-type allele ( Figure 1b) were obtained by interbreeding the heterozygous offspring, with the expected mendelian frequency. Two strains of P2Y 1 knockout mice were generated with identical phenotypes. These mice are viable, have no apparent morphological or physiological abnormalities, and display normal development, survival, and reproduction. The platelet count as well as other hematological parameters are identical to those of wild-type mice (Table 1 ). -/-and P2Y 1 +/+ mice. The 12-kb wild-type and 9.5-kb targeted BamHI fragments were identified using a probe located outside the 3′ limit of the construct (shown in a). Clones 187 and 26 (bold) were selected to be injected into blastocysts. 14.6 ± 0.8 14.1 ± 1.1
Mean ± SD (n = 4, except for platelet counts where n = 10).
Platelet aggregation is impaired in P2Y 1 -deficient mice. Functional studies of platelets from P2Y 1 -/-mice demonstrated a loss of ADP-induced aggregation and shape change at concentrations of ADP up to 10 µM, confirming the necessity of this receptor for ADPinduced platelet aggregation (Figure 2 ). Aggregation in response to 1.25 µg/mL collagen was strongly impaired, whereas the lag time in response to 5 µg/mL collagen was markedly prolonged in P2Y 1 -/-mice (25 seconds) as compared with the wild type (15 seconds). Conversely, aggregation in response to the TXA 2 mimetic U46619 or to thrombin was affected only at subthreshold concentrations of agonists (0.5 µM and 0.01 U/mL, respectively) (Figure 2 ). Heterozygous mice displayed an intermediate phenotype, i.e., decreased responses to ADP and to collagen as compared with the wild-type mice, but unchanged responses to the other agonists whatever the concentration tested (data not shown).
A potentiation role of ADP in P2Y 1 -/-mice through activation of the P2 receptor negatively coupled to adenylyl cyclase. Serotonin is a weak platelet agonist known to induce shape change only through activation of the 5HT 2A receptor and mobilization of intracellular calcium, which could be used to bypass the P2Y 1 receptor (10, 23) . Simultaneous addition of ADP (5 µM) and serotonin (1 µM) restored aggregation to ADP in P2Y 1 -/-platelets, suggesting the conservation of a potentiation role of ADP in P2Y 1 -/-mice. (Figure 3a) . This effect was due to activation of the P2 receptor negatively coupled to adenylyl cyclase because it was completely inhibited by addition of the ATP analogue AR-C69931MX (Figure 3a) . This was further confirmed by the observation that whereas the calcium response induced by ADP was abolished in the knockout mice (Figure 3b ), ADP still inhibited the PGE 1 -stimulated accumulation of cAMP in intact platelets (Figure 3c ), an effect inhibited by AR-C69931MX. These results demonstrate the existence of an ADP receptor, coupled to the inhibition of adenylyl cyclase, which is distinct from the P2Y 1 receptor.
Platelet aggregation by activation of the P2cyc receptor requires high concentrations of ADP. Addition of 100 µM ADP to washed platelets from P2Y 1 -/-mice resulted in a slow, gradual increase of light transmission up to 20% above the baseline at 5 minutes (Figure 4a , upper-right tracing) because of formation of small platelet aggregates without optically detectable shape change. The number of platelets in the aggregates was estimated by transmission electron microscopy to be between 5 and 10 ( Figure 4b, right panel) . This "partial platelet aggregation" occurred without detectable calcium movements ( Figure 3b 
Figure 2
In vitro aggregation responses of P2Y 1 -/-washed mice platelets as compared with wild-type. P2Y 1 -/-mice platelet aggregation is lost in response to ADP and strongly impaired in response to 1.25 µg/mL collagen, whereas the lag phase, measured from the addition of the agonist to starting of aggregation, is prolonged in response to 5 µg/mL collagen (25 seconds in P2Y 1 -/-versus 15 seconds in wildtype). In contrast, responses to thrombin and to U46619 were modified only at threshold concentrations. Bar: 1 minute. indicating that it occurred through activation of the P2cyc receptor. Epinephrine, even at 1 mM, did not induce such a response (data not shown (range 60-900 seconds, n = 43), and 126.6 ± 10 seconds for P2Y 1 +/+ (range 29-300 seconds, n = 80, with 1 mouse having a bleeding time of 800 seconds). The difference in bleeding time between the 2 populations is statistically significant (P < 0.0001, unpaired t test) ( Figure 5 ). However, increasing doses of ADP up to 500 mg/kg infused intravenously had no effect on the platelet count in P2Y 1 -/-mice as compared with wild-type mice where platelet counts were decreased by 50% (Figure 5b ), suggesting that platelets from P2Y 1 -/-mice are protected from in vivo ADP-induced platelet activation and removal from the circulation. Moreover, because collagen-induced platelet aggregation is strongly impaired, we measured the mortality induced by infusion of a mixture of collagen (0.5 mg/kg body weight) and epinephrine (60 µg/kg body weight). As shown in Figure  5c , 100% wild-type mice died within 4 minutes, whereas 50% of P2Y 1 -/-mice survived. These results demonstrate the key role of the P2Y 1 receptor in these acute thrombotic processes.
Discussion
We have generated P2Y 1 receptor-null mice in order to characterize the function of the P2Y 1 receptor in hemostasis and in thrombosis. These mice are viable, have no apparent morphological or physiological abnormalities and, so far, display normal development, survival and reproduction. This viability was somewhat surprising, since the P2Y 1 receptor is expressed early in embryonic development and throughout adult life in a wide range of tissues (7, 34) . It is possible that the role of the P2Y 1 receptor is discrete in all these tissues, or that its absence is overcome by the presence of other P2 receptors (7) .
In platelets, the P2Y 1 receptor has been shown to be necessary for ADP-induced aggregation (9) (10) (11) , whereas a separate P2 receptor coupled to inhibition of adenylyl cyclase is thought to complete and to amplify the response (11, 14, 16, 18) . However, doubts still remained as to whether the P2Y 1 receptor might be coupled to adenylyl cyclase inhibition, at least in native cells (35) . Functional studies of platelets from P2Y 1 -/-mice demonstrated a loss of ADP-induced aggregation, firmly establishing the requirement for this receptor for ADP-induced platelet aggregation (Figure 2) . Unexpectedly, aggregation in response to medium concentrations of collagen, able to sustain a full aggregation of wild-type platelets, was strongly impaired in P2Y 1 -/-platelets, whereas at higher concentrations the typical lag phase observed during collagen-induced aggregation was significantly prolonged (Figure 2 ). Collageninduced platelet activation is a complex process involving binding of collagen to at least 2 membrane proteins, the integrin α 2 β 1 and GPVI, tyrosine phosphorylation of cytosolic substrates, PLCγ2 activation, and finally generation of TXA 2 and release of ADP (36, 37) . Our results suggest an unsuspected role of the P2Y 1 receptor in the early phase of collagen-induced platelet activation that will deserve further characterization. Conversely, aggregation in response to the TXA 2 mimetic U46619 or to thrombin was affected only at threshold concentrations of agonists (Figure 2) . Strikingly, simultaneous addition of ADP and serotonin, used to bypass the P2Y 1 receptor (10, 23) , restored aggregation in P2Y 1 -/-platelets, demonstrating the conservation of a potentiation role of ADP in P2Y 1 -/-mice (Figure 3a) . This response was due to the P2cyc receptor because it was inhibited by the ATP analogue AR-C69931MX. Moreover, whereas the calcium response induced by ADP was abolished in the knock-out mice (Figure 3b ), ADP still inhibited the PGE 1 -stimulated accumulation of cAMP in intact platelets, this effect being blocked by AR-C69931MX (Figure 3c) . These results unambiguously demonstrate the existence of the putative P2cyc (13) (or P2T AC [14] or P2Y AC [15, 16] ) platelet ADP receptor, coupled to the inhibition of adenylyl cyclase, which is distinct from and independent of the P2Y 1 receptor.
The P2cyc receptor is believed to belong to the G protein-coupled receptor family on the basis of its coupling to the Gi 2 alpha subunit of heterotrimeric G proteins in photolabeling experiments (22) and its ability to inhibit cAMP accumulation. However, it is well-known that inhibition of adenylyl cyclase per se is not sufficient to trigger platelet aggregation (3) , and agonists such as epinephrine, acting by activation of Gi only, do not promote platelet aggregation (32) . However, we show here that a high concentration of ADP (100 µM) induces aggregation of P2Y 1 -/-mice platelets through activation of the P2cyc receptor ( Figure 4 ). This effect was observed in the absence of any calcium movement as measured using fura-2/AM-loaded platelets and without the classic disc-to-sphere transformation of platelets. In contrast to ADP, epinephrine did not induce such a response even at high concentrations (not shown). Together, these results indicate that activation of the P2cyc receptor triggers additional pathways in platelets, as compared with the α 2A adrenergic receptor, leading to the formation of microaggregates. Further studies should rapidly allow the fine characterization of the intracellular pathways involved when the P2cyc receptor is activated independently of the P2Y 1 receptor.
Despite the lack of platelet aggregation in response to ADP up to 10 µM, no bleeding, either spontaneous or during delivery, was observed in P2Y 1 -/-mice, although mean bleeding time in the knockout mice was nearly twice that of the wild-type mice. P2Y 1 -deficient mice displayed a strong resistance to thromboembolism induced by infusion of ADP (Figure 5b) or a mixture of collagen and epinephrine (Figure 5c ) as compared with wild-type mice. These observations demonstrate that the P2Y 1 receptor must play a key role in primary hemostasis and in thrombosis. To date, antithrombotic drugs selectively inhibiting ADP-induced platelet activation act on the P2cyc receptor without affecting the P2Y 1 receptor activation. These drugs are the thienopyridine compounds ticlopidine and clopidogrel or the ATP analogues termed AR-C66096, AR-C67085, and AR-C69931MX (13) (14) (15) (16) (17) . This study demonstrates that the P2Y 1 receptor is crucial under circumstances where collagen and ADP are the principal agents involved in platelet activation. Such circumstances are frequently encountered in small arteries where platelet interactions with the vessel wall are dependent mainly on collagen and the von Willebrand factor (38) during such clinical interventions as angioplasty, where deep injury of the vessel wall often results in vascular reocclusion (39) . In addition, platelet interactions with the vessel wall are mostly dependent on extracellular nucleotides and are regulated by the presence of ectonucleotidases, among which, CD39, the ATP diphosphohydrolase, has proved to be of major importance (40, 41) . Moreover, besides fibrin deposition in multiple organs because of deficiency in vascular protective effects, CD39 knock-out mice display an unexpected prolongation of the bleeding time because of selective desensitization of the P2Y 1 receptor (41). Thus, analogous to the unidentified P2 receptor sensitive to the thienopyridine clopidogrel, the P2Y 1 receptor represents a potential key pharmacological target for antithrombotic drugs. Such compounds would act in the early phase of platelet-vessel wall interactions through inhibition of ADP-and collagen-induced platelet activation. Finally, this strain of knockout mice should allow the investigation of other key roles that the P2Y 1 receptor may play, not only in the cardiovascular system, but also in all other tissues where it is expressed (7). 
